An Updated Systematic Review of Cost-Effectiveness Analyses of Drugs for Osteoporosis
ConclusionsThis updated review provides an overview of recently published cost-effectiveness analyses. In comparison with a previous review, recent economic evaluations of anti-osteoporosis drugs were conducted in more countries and included more active drugs and sequential therapy as interventions/comparators. The updated economic evidence could help decision makers prioritize health interventions and the unmet/unreported quality issues indicated by the osteoporosis-specific guideline could be useful in improving the transparency, quality, and comparability of future economic evaluations in osteoporosis.
Source: PharmacoEconomics - Category: Health Management Source Type: research
More News: Actonel | Databases & Libraries | Evista | Forteo | Gastroenterology | Health Management | Orthopaedics | Osteoarthritis | Osteoporosis | Reclast | Risedronate | Study | UK Health | Xgeva | Zometa